These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

220 related items for PubMed ID: 16563154

  • 1. Influence of the MDM2 single nucleotide polymorphism SNP309 on tumour development in BRCA1 mutation carriers.
    Copson ER, White HE, Blaydes JP, Robinson DO, Johnson PW, Eccles DM.
    BMC Cancer; 2006 Mar 24; 6():80. PubMed ID: 16563154
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. MDM2 SNP309 accelerates familial breast carcinogenesis independently of estrogen signaling.
    Wasielewski M, Nagel JH, Brekelmans C, Klijn JG, van den Ouweland A, Meijers-Heijboer H, Schutte M.
    Breast Cancer Res Treat; 2007 Aug 24; 104(2):153-7. PubMed ID: 17080308
    [Abstract] [Full Text] [Related]

  • 4. Effects of the single nucleotide polymorphism at MDM2 309 on breast cancer patients with/without BRCA1/2 mutations.
    Nechushtan H, Hamburger T, Mendelson S, Kadouri L, Sharon N, Pikarsky E, Peretz T.
    BMC Cancer; 2009 Feb 18; 9():60. PubMed ID: 19226467
    [Abstract] [Full Text] [Related]

  • 5. The single-nucleotide polymorphism 309 in the MDM2 gene contributes to the Li-Fraumeni syndrome and related phenotypes.
    Ruijs MW, Schmidt MK, Nevanlinna H, Tommiska J, Aittomäki K, Pruntel R, Verhoef S, Van't Veer LJ.
    Eur J Hum Genet; 2007 Jan 18; 15(1):110-4. PubMed ID: 17003841
    [Abstract] [Full Text] [Related]

  • 6. Association of breast cancer outcome with status of p53 and MDM2 SNP309.
    Boersma BJ, Howe TM, Goodman JE, Yfantis HG, Lee DH, Chanock SJ, Ambs S.
    J Natl Cancer Inst; 2006 Jul 05; 98(13):911-9. PubMed ID: 16818855
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Association between a functional single nucleotide polymorphism in the MDM2 gene and sporadic endometrial cancer risk.
    Walsh CS, Miller CW, Karlan BY, Koeffler HP.
    Gynecol Oncol; 2007 Mar 05; 104(3):660-4. PubMed ID: 17123590
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Lack of association between the MDM2-SNP309 polymorphism and breast cancer risk.
    Petenkaya A, Bozkurt B, Akilli-Ozturk O, Kaya HS, Gur-Dedeoglu B, Yulug IG.
    Anticancer Res; 2006 Mar 05; 26(6C):4975-7. PubMed ID: 17214373
    [Abstract] [Full Text] [Related]

  • 13. Combined effects of single nucleotide polymorphisms TP53 R72P and MDM2 SNP309, and p53 expression on survival of breast cancer patients.
    Schmidt MK, Tommiska J, Broeks A, van Leeuwen FE, Van't Veer LJ, Pharoah PD, Easton DF, Shah M, Humphreys M, Dörk T, Reincke SA, Fagerholm R, Blomqvist C, Nevanlinna H.
    Breast Cancer Res; 2009 Mar 05; 11(6):R89. PubMed ID: 20021639
    [Abstract] [Full Text] [Related]

  • 14. MDM2 SNP309 is associated with poor outcome in B-cell chronic lymphocytic leukemia.
    Gryshchenko I, Hofbauer S, Stoecher M, Daniel PT, Steurer M, Gaiger A, Eigenberger K, Greil R, Tinhofer I.
    J Clin Oncol; 2008 May 10; 26(14):2252-7. PubMed ID: 18467716
    [Abstract] [Full Text] [Related]

  • 15. MDM2 SNP309 polymorphism as risk factor for susceptibility and poor prognosis in renal cell carcinoma.
    Hirata H, Hinoda Y, Kikuno N, Kawamoto K, Suehiro Y, Tanaka Y, Dahiya R.
    Clin Cancer Res; 2007 Jul 15; 13(14):4123-9. PubMed ID: 17634539
    [Abstract] [Full Text] [Related]

  • 16. The MDM2 promoter polymorphism SNP309T-->G and the risk of uterine leiomyosarcoma, colorectal cancer, and squamous cell carcinoma of the head and neck.
    Alhopuro P, Ylisaukko-Oja SK, Koskinen WJ, Bono P, Arola J, Järvinen HJ, Mecklin JP, Atula T, Kontio R, Mäkitie AA, Suominen S, Leivo I, Vahteristo P, Aaltonen LM, Aaltonen LA.
    J Med Genet; 2005 Sep 15; 42(9):694-8. PubMed ID: 16141004
    [Abstract] [Full Text] [Related]

  • 17. MDM2 promoter polymorphism is associated with both an increased susceptibility to gastric carcinoma and poor prognosis.
    Ohmiya N, Taguchi A, Mabuchi N, Itoh A, Hirooka Y, Niwa Y, Goto H.
    J Clin Oncol; 2006 Sep 20; 24(27):4434-40. PubMed ID: 16983111
    [Abstract] [Full Text] [Related]

  • 18. Mdm2 SNP309 G-variant is associated with invasive growth of human urinary bladder cancer.
    Hitzenbichler F, Stoehr CG, Rogenhofer M, Wieland WF, Ruemmele P, Hartmann A, Stoehr R.
    Pathobiology; 2014 Sep 20; 81(2):53-9. PubMed ID: 24217660
    [Abstract] [Full Text] [Related]

  • 19. Association of the germline TP53 R72P and MDM2 SNP309 variants with breast cancer survival in specific breast tumor subgroups.
    van den Broek AJ, Broeks A, Horlings HM, Canisius SV, Braaf LM, Langerød A, Van't Veer LJ, Schmidt MK.
    Breast Cancer Res Treat; 2011 Nov 20; 130(2):599-608. PubMed ID: 21667122
    [Abstract] [Full Text] [Related]

  • 20. Effects of MDM2, MDM4 and TP53 codon 72 polymorphisms on cancer risk in a cohort study of carriers of TP53 germline mutations.
    Fang S, Krahe R, Lozano G, Han Y, Chen W, Post SM, Zhang B, Wilson CD, Bachinski LL, Strong LC, Amos CI.
    PLoS One; 2010 May 26; 5(5):e10813. PubMed ID: 20520810
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.